Cover Image
市場調查報告書

多形性膠質母細胞瘤 (GBM) 治療的全球市場 - 2014∼2022年:產業分析、規模、佔有率、成長、趨勢及預測

Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

出版商 Transparency Market Research 商品編碼 335190
出版日期 內容資訊 英文 101 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多形性膠質母細胞瘤 (GBM) 治療的全球市場 - 2014∼2022年:產業分析、規模、佔有率、成長、趨勢及預測 Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
出版日期: 2015年06月10日 內容資訊: 英文 101 Pages
簡介

多形性膠質母細胞瘤 (GBM) 是在成人中最常發生的致命性原發性腦瘤。現在市場上可利用的治療方法為手術的切除,加上化療,放射線治療,不過,無法提高患者的整體存活率。這樣的治療方法無效的主要理由是,頻繁的復發,GBM的侵入性,並且神經膠質瘤幹細胞對傳統治療的抗性等。因此新的治療策略是必須由於分子生物學和遺傳基因技術的進步,對確診為GBM的患者來說找到新治療方法的可能性。

本報告提供全球多形性膠質母細胞瘤 (GBM) 治療市場相關詳細分析、2012∼2022年的成長預測、各藥物、各地區趨勢、治療開發平台,及參與企業簡介彙整。

第1章 序論

第2章 摘要整理

第3章 市場概要

  • 簡介和市場定義
  • 疾病概要
    • 多形性膠質母細胞瘤的亞型
    • 流行病學
    • 標準的治療方法和替代的治療方法
  • 核酸遞送法
  • 診斷的體外GBM鑑定
  • 純粹分子遞送系統
  • 市場趨勢
    • 促進要素
      • 易得GBM的高齡人口增加帶動GBM治療市場
      • 全球性高齡化
      • 各個政府及非政府團體提高GBM的認識
    • 阻礙要素
      • GBM由於對DNA修飾劑有高抗性治療方法受限
      • 現在FDA認可的治療方法使整體生存期間變短
    • 市場機會
      • 開發凌駕目前治療方法的新藥物遞輸系統的免疫治療和生物學治療方法
  • 活動影響分析
  • 各藥物市場收益及預測:2012∼2022年
  • 各地區市場收益及預測:2012∼2022年
    • 北美
    • 歐洲
    • 亞太地區
    • 其他
  • 競爭環境

第4章 全球多形性膠質母細胞瘤治療開發平台評估

  • 概要
  • 開發平台分析
    • 標靶治療
    • 基因治療
    • 免疫治療
  • 第一階段、第二階段藥物

第5章 建議

第6章 企業簡介

  • AbbVie, Inc.
  • Activartis GmbH
  • Agenus Inc.
  • Arog Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Cavion LLC
  • Celldex Therapeutics Inc
  • CTI BioPharma Corporation
  • Cortice Biosciences Inc.
  • 株式會社Eisai
  • Exelixis Inc.
  • Hoffmann-La Roche Ltd.
  • Peregrine Pharmaceuticals, Inc.
  • OncoSynergy
  • Merrimack Pharmaceuticals, Inc.

圖表

目錄

Glioblastoma multiforme (GBM) is the most frequent and lethal primary brain tumor in adults. The current treatment modalities available in the market are surgical resection followed by chemotherapy and radiotherapy, that unable to increase the overall survival of patient. The main reason behind inability of these treatments are frequent recurrence, invasiveness of GBM and resistance of glioma stem cells to conventional treatments. Therefore, novel alternative treatment strategies are desperately needed and pipeline of GBM already involves a mix of biological, immunotherapy, small molecules and other types of therapeutics. Recent advancements in molecular biology and gene technology have provided attractive novel treatment possibilities for the patients diagnosed with GBM.

This research report on the glioblastoma treatment market explains various advancements in this market and analyzes the global glioblastoma treatment market based on drugs (commercially available and pipeline) and geographic regions. The report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments dominating the market and expected to grow at the highest growth rate during the forecast period are included in the report in a precise manner.

A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global glioblastoma treatment market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis and Porter's Five Forces analysis and key players' market share analysis in 2013 in the glioblastoma treatment market. The research report also provides event impact analysis and various drug delivery methods such as nucleic acid delivery method and biomedical delivery method for the treatment of glioblastoma.

Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. The report on glioblastoma market also provides % compound annual growth rate (CAGR) for each of the market segments mentioned above for the forecast period from 2014 to 2022, considering 2013 as the base year.

Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II). Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022. The report on the glioblastoma treatment market also provides % compound annual growth rate (CAGR) for each of the phase III molecules individually for the forecast period from 2014 to 2022.

Geographically, the glioblastoma treatment market has been categorized into North America, Europe, Asia-Pacific and Rest of the World. The market size and forecast for each of these regions have been provided for the period from 2012 to 2022 along with CAGR (%) for the forecast period from 2014 to 2022.

A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics.

The pipeline review of glioblastoma treatment market has been segmented as below:

Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs

  • Bevacizumab (Avastin)
  • Temozolomide (Temodar and Temodal and Temcad)
  • Carmustine (BiCNU)

Global Glioblastoma Treatment Market Revenue and Forecast, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Global Pipeline Review of Glioblastoma Treatment

  • Overview
  • Late Stage (Phase III)
    • DCVax
    • Rindopepimut (CDX-110)
    • Others
  • Early Stage (Phase I, II and Pre clinical)
    • ABT-414
    • MM-398
    • ARC-100
    • AV0113
    • Cotara
    • Crenolanib
    • SGT-53
    • Endostatin
    • ANG1005
    • Others

Table of Contents

Chapter 1 Preface

  • 1.1 Report Description

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2022)
  • 2.2 Global Glioblastoma Multiforme Treatment Market, by Drug, 2013 (USD Million)
  • 2.3 Comparative Analysis: Glioblastoma Multiforme Treatment Market, by Geography, 2013 and 2022 (Value %)

Chapter 3 Market Overview

  • 3.1 Introduction and Market Definition
  • 3.2 Disease Overview
    • 3.2.1 Subtypes of Glioblastoma Multiforme
      • 3.2.1.1 Signatures and Clinical features of GBM subtypes
    • 3.2.2 Epidemiology
    • 3.2.3 Standard treatment options and alternative therapeutics approaches
  • 3.3 Nucleic Acid Delivery Methods
    • 3.3.1 Virus-based
    • 3.3.2 Nonviral-based
    • 3.3.3 Stem cells
  • 3.4 In Vivo Identification of GBM for Diagnostic Implication
    • 3.4.1 Magnetic Resonance Imaging (MRI)
    • 3.4.2 Computed Tomography (CT)
    • 3.4.3 Positron Emission Tomography (PET)
    • 3.4.4 Others
  • 3.5 Biomolecule delivery systems
    • 3.5.1 For Glioblastoma
      • 3.5.1.1 Example of homing targets, polymeric coatings, nanoparticle configurations, and therapeutic agents utilized in nanoparticle drug delivery for glioma
    • 3.5.2 For other Central Nervous System (CNS) disorders
  • 3.6 Market Dynamics
    • 3.6.1 Drivers
      • 3.6.1.1 Rising geriatric population will drive the GBM treatment market as they are more prone to cause GBM
      • 3.6.1.2 Global Rate of Aging Population
      • 3.6.1.3 Various government and non-government organizations are creating worldwide awareness against GBM
    • 3.6.1.4 The future of glioblastoma treatment market expects introduction of several novel therapies due to its strong pipeline
    • 3.6.2 Restraints
      • 3.6.2.1 GBM is highly resistant to DNA modifying agents hence available therapies have limitations
      • 3.6.2.2 The overall survival period delivered by current FDA approved treatments is less
    • 3.6.3 Opportunities
      • 3.6.3.1 Development of immunotherapy and biological therapy treatments along with novel drug delivery systems add advantage over the current conventional treatments
  • 3.7 Event Impact Analysis
  • 3.8 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 - 2022 (USD Million)
    • 3.8.1 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 - 2022 (USD Million)
    • 3.8.2 Bevacizumab (Avastin)
      • 3.8.2.1 Global Bevacizumab Market Revenue, 2012 - 2022 (USD Million)
    • 3.8.3 Temozolomide
      • 3.8.3.1 Global Temozolomide Market Revenue, 2012 - 2022 (USD Million)
    • 3.8.4 Carmustine (BiCNU)
      • 3.8.4.1 Global Carmustine (BiCNU) Market Revenue, 2012 - 2022 (USD Million)
  • 3.9 Global Glioblastoma Treatment Market Revenue and Forecast, by Geography, 2012 - 2022 (USD Million)
    • 3.9.1 North America
      • 3.9.1.1 North America Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
    • 3.9.2 Europe
      • 3.9.2.1 Europe Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
    • 3.9.3 Asia Pacific
      • 3.9.3.1 Asia Pacific Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
    • 3.9.4 Rest of the World (RoW)
      • 3.9.4.1 Rest of the World Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
  • 3.10 Competitive Landscape
    • 3.10.1 Global Glioblastoma Treatment Market: Market Share, by Key Players 2013 (%)

Chapter 4 Global Pipeline Review of Glioblastoma Treatment

  • 4.1 Overview
  • 4.2 Pipeline Analysis : Types of Therapies
    • 4.2.1 Targeted Therapy
      • 4.2.1.1 TRC-105
    • 4.2.2 Gene Therapy
      • 4.2.2.1 VB-111
      • 4.2.2.2 TOCA 511
    • 4.2.3 Immunotherapy
      • 4.2.3.1 DCVax-Brain
      • 4.2.3.2 Rindopepimut (CDX-110)
      • 4.2.3.3 Phase II (ACT II, ACT III and ACTIVATE) trial results of Rindopepimut
      • 4.2.3.4 ICT-107
      • 4.2.3.5 Trivax (AV00113)
  • 4.3 Phase I and II Drug Entities

Chapter 5 Recommendations

  • 5.1 Market Strategy for Success
    • 5.1.1 Focus on the development of immunotherapy and biological therapy treatments
    • 5.1.2 Development of novel drug delivery system (NDDS)
    • 5.1.3 Expected intense competition in the near future

Chapter 6 Company Profiles

  • 6.1 AbbVie, Inc.
    • 6.1.1 Company Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Product Portfolio
    • 6.1.4 Business Strategies
      • 6.1.4.1 Acquisitions and partnership for market penetration
    • 6.1.5 Recent Developments
  • 6.2 Activartis GmbH
    • 6.2.1 Company Overview
    • 6.2.2 Financial Overview
  • Being a privately owned company, the financial results of Activartis Biotech GmbH is not available in the public domain.
    • 6.2.3 Product Portfolio
    • 6.2.4 Business Strategies
      • 6.2.4.1 Strong focus on research and development
    • 6.2.5 Recent Developments
  • 6.3 Agenus Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Product Portfolio
    • 6.3.4 Business Strategies
      • 6.3.4.1 Acquisition & Merger
    • 6.3.5 Recent Developments
  • 6.4 Arog Pharmaceuticals, Inc.
    • 6.4.1 Company Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Product Portfolio
    • 6.4.4 Business Strategies
      • 6.4.4.1 Research and development
    • 6.4.5 Acquisition of worldwide rights
    • 6.4.6 Recent Developments
  • 6.5 Bristol-Myers Squibb Company
    • 6.5.1 Company Overview
    • 6.5.2 Financial Overview
    • 6.5.3 Product Portfolio
    • 6.5.4 Business Strategies
      • 6.5.4.1 Acquisitions for company's growth
    • 6.5.5 Recent Developments
  • 6.6 Cavion LLC
    • 6.6.1 Company Overview
    • 6.6.2 Financial Overview
    • 6.6.3 Product Portfolio
    • 6.6.4 Business Strategies
      • 6.6.4.1 New Drug Development
  • 6.7 Celldex Therapeutics Inc.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Overview
    • 6.7.3 Product Portfolio
    • 6.7.4 Business Strategies
      • 6.7.4.1 Strong Pipeline portfolio
    • 6.7.5 Recent Developments
  • 6.8 CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
    • 6.8.1 Company Overview
    • 6.8.2 Financial Overview
    • 6.8.3 Product Portfolio
    • 6.8.4 Business Strategies
      • 6.8.4.1 Strong Pipeline portfolio
    • 6.8.5 Recent Developments
  • 6.9 Cortice Biosciences Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Overview
    • 6.9.3 Product Portfolio
    • 6.9.4 Business Strategies
      • 6.9.4.1 Acquisition of Exclusive Commercial Rights
    • 6.9.5 Recent Developments
  • 6.10 Eisai Co., Ltd.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Overview
    • 6.10.3 Product Portfolio
    • 6.10.4 Business Strategies
      • 6.10.4.1 Joint Research Agreement
      • 6.10.4.2 Introduction of new lifestyle information website for breast cancer patients
    • 6.10.5 Recent Developments
  • 6.11 Exelixis Inc.
    • 6.11.1 Company Overview
    • 6.11.2 Financial Overview
    • 6.11.3 Product Portfolio
    • 6.11.4 Business Strategies
      • 6.11.4.1 Strong Pipeline portfolio
      • 6.11.4.2 Partnered compounds
    • 6.11.5 Recent Developments
  • 6.12 F. Hoffmann-La Roche Ltd.
    • 6.12.1 Company Overview
    • 6.12.2 Financial Overview
    • 6.12.3 Product Portfolio
    • 6.12.4 Business Strategies
      • 6.12.4.1 Investment in research and development (R&D)
      • 6.12.4.2 Strengthening core business
      • 6.12.4.3 Mergers and Acquisitions
    • 6.12.5 Recent Developments
  • 6.13 Peregrine Pharmaceuticals, Inc.
    • 6.13.1 Company Overview
    • 6.13.2 Financial Overview
    • 6.13.3 Product Portfolio
    • 6.13.4 Business Strategies
      • 6.13.4.1 Licensing agreements and collaborations
      • 6.13.4.2 Research and development approach
    • 6.13.5 Recent Developments
  • 6.14 OncoSynergy
    • 6.14.1 Company Overview
    • 6.14.2 Financial Overview
    • 6.14.3 Product Portfolio
    • 6.14.4 Business Strategies
    • 6.14.5 Recent Developments
  • 6.15 Merrimack Pharmaceuticals, Inc.
    • 6.15.1 Company Overview
    • 6.15.2 Financial Overview
    • 6.15.3 Product Portfolio
    • 6.15.4 Business Strategies
    • 6.15.4.1 Acquisition and collaboration agreement to gain market share
    • 6.15.5 Recent Developments

List of Figures

  • FIG. 1 Global Glioblastoma Multiforme Treatment Market, by Drug, 2013 (USD Million)
  • FIG. 2 Comparative Analysis: Glioblastoma Multiforme Treatment Market, by Geography, 2013 and 2022 (Value %)
  • FIG. 3 Median Overall Survival Time of Glioblastoma Patients, by Therapy
  • FIG. 4 Global Rate of Aging Population
  • FIG. 5 Global Glioblastoma Treatment Market: Event Impact Analysis
  • FIG. 6 Global Bevacizumab Market Revenue, 2012 - 2022 (USD Million)
  • FIG. 7 Global Temozolomide Market Revenue, 2012 - 2022 (USD Million)
  • FIG. 8 Global Carmustine (BiCNU) Market Revenue, 2012 - 2022 (USD Million)
  • FIG. 9 North America Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
  • FIG. 10 Europe Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
  • FIG. 11 Asia Pacific Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
  • FIG. 12 Rest of the World Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
  • FIG. 13 Global Glioblastoma Treatment Market: Market Share, by Key Players 2013 (%)
  • FIG. 14 Pipeline Analysis: Glioblastoma Treatment
  • FIG. 15 AbbVie, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 16 Agenus Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 17 Bristol-Myers Squibb Company: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 18 Eisai Co., Ltd.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 19 Exelxis Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 20 F. Hoffmann-La Roche Ltd: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 21 Peregrine Pharmaceuticals, Inc.: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2022) 15
  • TABLE 2 Signatures and Clinical features of GBM subtypes 21
  • TABLE 3 Example of homing targets, polymeric coatings, nanoparticle configurations, and therapeutic agents utilized in nanoparticle drug delivery for glioma 32
  • TABLE 4 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 - 2022 (USD Million) 40
  • TABLE 5 Phase II (ACT II, ACT III and ACTIVATE) trial results of Rindopepimut 58
Back to Top